Efficacy of tolvaptan in patients with refractory ascites in a clinical setting - Wikidata - awgldk - TriplyDB

Efficacy of tolvaptan in patients with refractory ascites in a clinical setting

Efficacy of tolvaptan in patients with refractory ascites in a clinical setting

http://www.wikidata.org/entity/Q40771170

about

Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.Predictive parameter of tolvaptan effectiveness in cirrhotic ascites.Ascites, refractory ascites and hyponatremia in cirrhosis.Potential Effectiveness of Tolvaptan to Improve Ascites Unresponsive to Standard Diuretics and Overall Survival in Patients with Decompensated Liver Cirrhosis.Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.Tolvaptan for the Treatment of Refractory Ascites.Tolvaptan is effective in treating patients with refractory ascites due to cirrhosis.Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis.Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria.Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema.Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites.Management of refractory cirrhotic ascites: challenges and solutions

P2860

Q36330332-CD8BF277-7AEA-4032-A759-252CE4375DFF Q39321625-C7280F18-D53C-411C-8624-003107044E30 Q39323841-D35E92A2-C9DF-40C9-8604-DC01E4F4318F Q40654657-034DC7E6-D921-4CB7-A088-6C062408C3EB Q41334703-869A2E25-D464-4DCE-BB1A-42D164DB6B40 Q42368708-6CE77961-FA39-4702-A4D9-5E0B3FBAA559 Q47139485-870029E3-A141-4493-84DB-FE6E4B10228B Q47688442-1E5E451C-EBC0-435D-BFEA-B9B1E262538F Q47732990-71A4C8ED-5D6E-4CD3-8B83-F0EEB62FC9A1 Q50277167-33A4D522-F316-49BD-BC6D-93BC68974D26 Q51623426-188888E9-BB49-472D-9645-CF802DF513F7 Q51793798-7C8D8D5B-A783-40F7-91AB-02833C108BAB Q57407557-C4FA31AF-07CF-4602-B5F3-64245907949D

P2860

Efficacy of tolvaptan in patients with refractory ascites in a clinical setting

http://www.wikidata.org/entity/Q40771170

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Efficacy of tolvaptan in patients with refractory ascites in a clinical setting

@en

type

label

Efficacy of tolvaptan in patients with refractory ascites in a clinical setting

@en

prefLabel

Efficacy of tolvaptan in patients with refractory ascites in a clinical setting

@en

P1433

Q40771170-C3B2CE32-1C04-40F1-AAD7-23FC6DD59217

P1476

Q40771170-495E9204-1B93-4C42-8AF0-6BDE24AE3DA7

P2093

Q40771170-058438D5-6851-4A2F-B61B-475DC55318A4

Q40771170-3AFA0EC8-57BF-4408-AA4A-494C34BC8517

Q40771170-667708A2-1D09-4E9C-B25F-F945C021A420

Q40771170-70778E93-437F-485C-A0FF-5373ED120474

Q40771170-8EF7FCA4-06CC-4284-ABF8-5844562FE367

Q40771170-953E239F-C9E3-4E96-A844-D9E4C1A8750B

Q40771170-AB5576EB-C96E-468D-B985-3EE58DA92681

Q40771170-B8468CE8-3851-4EF2-983E-20519F51F871

Q40771170-BF1B4B99-2AA9-41D0-ABD1-FA5065A3D395

Q40771170-E24C2FC1-D1F0-4A15-97DF-88E82DE70244

P2860

Q40771170-0C3DDE1D-645B-4738-BD0C-BFE4B53EA3A4

Q40771170-13DFB461-B9E5-4323-B73A-C308E6C728E0

Q40771170-170A4B04-B186-4976-A054-4DDA6B159CCF

Q40771170-1EE33746-CB7B-4C3F-B030-A6958112137C

Q40771170-21855E9B-C944-48E4-9410-A6F2CDD10499

Q40771170-2DCF5923-152D-4D36-91D1-761BD33BFDDA

Q40771170-303337EE-1F67-4594-81D9-09C46DA6B791

Q40771170-58B8BBCE-4361-4E4D-89EF-B2E91618BF4D

Q40771170-610450AE-909D-4163-BDE9-B924BE8AC2EC

Q40771170-62F961CE-F551-4D92-99BC-A85FD01EA846

P304

Q40771170-69985FF2-4CAF-45F0-B972-A059D7814C72

P31

Q40771170-AEF02EA3-4F41-4A86-902B-C809B59DE9F1

P356

Q40771170-5F826000-6B32-4D80-BFEF-113BC1216237

P433

Q40771170-24CCD6AB-D4EA-4CEB-976C-CD8998B2130F

P478

Q40771170-35690399-1A61-4DA6-87DB-CCBB37D15E60

P577

Q40771170-881D5EC4-7981-4371-98A3-063661A8A506

P698

Q40771170-9E860691-E54C-46F3-8656-78CF7CCA663B

P932

Q40771170-A0EE2E10-9127-4BC8-9301-EDB0101CAFEF

P356

WJH.V7.I12.1685

P1433

World journal of hepatology

P1476

Efficacy of tolvaptan in patients with refractory ascites in a clinical setting

@en

P2093

Daisaku Ito

http://www.w3.org/2001/XMLSchema#string

Kazumi Tagawa

http://www.w3.org/2001/XMLSchema#string

Kentaro Kojima

http://www.w3.org/2001/XMLSchema#string

Koki Kawanishi

http://www.w3.org/2001/XMLSchema#string

Koki Sato

http://www.w3.org/2001/XMLSchema#string

Mari Yamagami

http://www.w3.org/2001/XMLSchema#string

Michiharu Seki

http://www.w3.org/2001/XMLSchema#string

Nobuo Toda

http://www.w3.org/2001/XMLSchema#string

Takamasa Ohki

http://www.w3.org/2001/XMLSchema#string

Tomoharu Yamada

http://www.w3.org/2001/XMLSchema#string

P2860

The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club.

Management of cirrhosis and ascites.

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.

Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Non-peptide arginine-vasopressin antagonists: the vaptans.

Management of hyponatremia: providing treatment and avoiding harm.

Tolvaptan for the treatment of heart failure: a review of the literature.

Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry.

Tolvaptan for the treatment of hyponatremia and congestive heart failure.

P304

1685-1693

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4254/WJH.V7.I12.1685

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26140088

http://www.w3.org/2001/XMLSchema#string

P932

4483550

http://www.w3.org/2001/XMLSchema#string